Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia

INTRODUCTION: Coronavirus disease 2019 (COVID-19) can progress to severe respiratory compromise and lead to mortality due to induction of cytokine storm. Tocilizumab (TCZ) is approved by the FDA for the treatment of cytokine release syndrome (CRS). This study aims to analyze the outcomes among patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Alex, Ruth, Gulam, Shabaz Mohiuddin, Kumar, Kiran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203205/
https://www.ncbi.nlm.nih.gov/pubmed/35721667
http://dx.doi.org/10.1155/2022/7060466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203205/
https://www.ncbi.nlm.nih.gov/pubmed/35721667
http://dx.doi.org/10.1155/2022/7060466

Ejemplares similares